Disorders of Pigmentation of the Skin - Hypotheses Underlying Interventions by Multiple Systems of Medicine:Is there a Role for Integrated Medicine?

Biomedicine has not provided a complete explanation with fully effective therapies for disorders of pigmentation. Biomedicine emphasizes the role of melanocyte for protection from UV rays and as a determinant of skin colour. These important properties acquired a genetic basis much later than other functions, many relating to cell contact as in the keratinocyte - melanocyte unit, or as with the synapses of the neurological system. There are other roles, biochemical and mechanical, of melanocyte. Management that is inclusive of a maximally holistic approach justifies the use of diverse herbals, yoga and concern for cultural awareness provided by integrated medicine. Vitiligo provides a model which demonstrates that Ayurveda has a richer view of its presentations, possibly a stronger line on its pathogenesis, and a huge range of herbals, many now backed by studies from ethnobotanical laboratories, awaiting research into the many possible mechanisms by which they may act in the wide and complex field of melanocyte biochemistry.

[1]  Y. Lee,et al.  Proton pump inhibitors as a possible cause of vitiligo: an in vivo and in vitro study , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  T. Ryan,et al.  Human pigmentation: A side effect adapted from a primitive organism's survival. Part 2: The melanocyte as mentor of the keratinocye , 2014, Indian dermatology online journal.

[3]  T. Ryan,et al.  Human pigmentation: A side effect adapted from a primitive organism's survival, acting through cell attachment with an affinity for the keratinocyte and for elastin: Part I , 2014, Indian dermatology online journal.

[4]  Q. Sun,et al.  Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  M. Chatterjee,et al.  Pigmentary Disorders: A Comprehensive Compendium , 2014 .

[6]  J. Na,et al.  Effect of tranexamic acid on melasma: a clinical trial with histological evaluation , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  M. Zheng,et al.  Expression of pigment epithelium‐derived factor in human cutaneous appendages , 2013, Clinical and experimental dermatology.

[8]  K. Burr,et al.  Reprogramming Adult Schwann Cells to Stem Cell-like Cells by Leprosy Bacilli Promotes Dissemination of Infection , 2013, Cell.

[9]  O. Shaker,et al.  Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  L. Kolbe,et al.  4‐n‐butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  M. Brilliant,et al.  Albinism and disease causing pathogens in Tanzania: are alleles that are associated with OCA2 being maintained by balancing selection? , 2012, Medical hypotheses.

[12]  G. Loussouarn,et al.  Greying of the human hair: a worldwide survey, revisiting the ‘50’ rule of thumb , 2012, The British journal of dermatology.

[13]  Q. Shi,et al.  The association of vitamin D receptor gene polymorphisms and serum 25‐hydroxyvitamin D levels with generalized vitiligo , 2012, The British journal of dermatology.

[14]  Blazej Zbytek,et al.  Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. , 2012, Advances in anatomy, embryology, and cell biology.

[15]  Ai-Young Lee Role of Keratinocytes in the Development of Vitiligo , 2012, Annals of dermatology.

[16]  T. Jouary,et al.  Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo , 2012, The British journal of dermatology.

[17]  H. Y. Kang,et al.  Pendulous melanocytes: a characteristic feature of melasma and how it may occur , 2012, The British journal of dermatology.

[18]  P. Bahadoran,et al.  Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations , 2012, The British journal of dermatology.

[19]  H. Y. Kang,et al.  Defective barrier function in melasma skin , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[20]  A. Pandya Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo , 2012 .

[21]  W. Westerhof,et al.  The effect of H₁ and H₂ receptor antagonists on melanogenesis. , 2012, Indian journal of dermatology, venereology and leprology.

[22]  J. Leyden,et al.  Natural options for the management of hyperpigmentation , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  T. Ruzicka,et al.  Dead Sea climatotherapy for vitiligo: a retrospective study of 436 patients , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  D. Kaul,et al.  Altered levels of Ets‐1 transcription factor and matrix metalloproteinases in melanocytes from patients with vitiligo , 2011, The British journal of dermatology.

[25]  T. Ryan,et al.  Collaboration with traditional health practitioners in the provision of skin care for all in Africa , 2011, International journal of dermatology.

[26]  T. Ryan,et al.  Integrating modern dermatology and Ayurveda in the treatment of vitiligo and lymphedema in India , 2011, International journal of dermatology.

[27]  I. Han,et al.  Keratinocyte-derived Laminin-332 Promotes Adhesion and Migration in Melanocytes and Melanoma* , 2011, The Journal of Biological Chemistry.

[28]  N. Mackman,et al.  Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. , 2010, Blood.

[29]  Saravu R Narahari,et al.  A protocol for systematic reviews of Ayurveda treatments , 2010, International journal of Ayurveda research.

[30]  J. Tang,et al.  Abnormal DNA methylation in peripheral blood mononuclear cells from patients with vitiligo , 2010, The British journal of dermatology.

[31]  P. Elias,et al.  Epidermal Permeability Barrier Recovery Is Delayed in Vitiligo-Involved Sites , 2010, Skin Pharmacology and Physiology.

[32]  G. Lauzon,et al.  Analysis of interleukin‐10 levels in lesions of vitiligo following treatment with topical tacrolimus , 2009, The British journal of dermatology.

[33]  H. Kittler,et al.  Response of vitiligo to once‐ vs. twice‐daily topical tacrolimus: a controlled prospective, randomized, observer‐blinded trial , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[34]  T. Anbar,et al.  The hair follicle melanocytes in vitiligo in relation to disease duration , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[35]  D. Bani,et al.  Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. , 2009, Histology and histopathology.

[36]  K. Ha,et al.  Co‐localization of inducible nitric oxide synthase and phosphorylated Akt in the lesional skins of patients with melasma , 2009, The Journal of dermatology.

[37]  G. Schoolnik,et al.  Role of Melanin Pigment in Expression of Vibrio cholerae Virulence Factors , 2008, Infection and Immunity.

[38]  M J Watts,et al.  Guideline for the diagnosis and management of vitiligo , 2008, The British journal of dermatology.

[39]  Ji-won Park,et al.  Molecular Control of Phenoloxidase-induced Melanin Synthesis in an Insect*♦ , 2008, Journal of Biological Chemistry.

[40]  M. Namazi Proton pump inhibitors may trigger vitiligo by rendering melanocytes prone to apoptosis , 2008, The British journal of dermatology.

[41]  H. Rokos,et al.  From the bench to the bedside: proton pump inhibitors can worsen vitiligo , 2007, The British journal of dermatology.

[42]  C‐S. Wu,et al.  Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo , 2007, The British journal of dermatology.

[43]  P. Grimes,et al.  The safety of hydroquinone , 2006, Journal of cosmetic dermatology.

[44]  J. Reichrath,et al.  Cutaneous photosynthesis of vitamin D: an evolutionary highly-conserved endocrine system that protects against environmental hazards including UV-radiation and microbial infections. , 2006, Anticancer research.

[45]  O. Turan,et al.  Audiological abnormalities in patients with vitiligo , 2006, Clinical and experimental dermatology.

[46]  Murad Alam The Book of Skin , 2006 .

[47]  M. Pittelkow,et al.  Increased monoamine oxidase A activity in the epidermis of patients with vitiligo , 2006, Archives of Dermatological Research.

[48]  C. Lan,et al.  FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo , 2005, The British journal of dermatology.

[49]  G. Dogan,et al.  A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients , 2005, International journal of dermatology.

[50]  W. Westerhof,et al.  Toxicology and health risks of hydroquinone in skin lightening formulations , 2005 .

[51]  T. Hirobe Role of keratinocyte-derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes. , 2005, Pigment cell research.

[52]  M. Can,et al.  The role of oxidants and antioxidants in generalized vitiligo at tissue level , 2004, Journal of the European Academy of Dermatology and Venereology : JEADV.

[53]  Graeme Eisenhofer,et al.  Tyrosinase: a developmentally specific major determinant of peripheral dopamine , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  J. Dangou,et al.  Irrational use of skin-bleaching products can delay the diagnosis of leprosy. , 2002, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[55]  W. Steglich,et al.  Pityriacitrin – an ultraviolet-absorbing indole alkaloid from the yeast Malassezia furfur , 2002, Archives of Dermatological Research.

[56]  S. Sohn,et al.  Melasma: histopathological characteristics in 56 Korean patients , 2002, The British journal of dermatology.

[57]  J. Mackintosh The antimicrobial properties of melanocytes, melanosomes and melanin and the evolution of black skin. , 2001, Journal of theoretical biology.

[58]  H. Lim,et al.  Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. , 2001, Journal of the American Academy of Dermatology.

[59]  J. Park,et al.  Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase‐related protein in vitiligo , 2001, The British journal of dermatology.

[60]  G. Vezon,et al.  High prevalence of vitiligo in lepromatous leprosy , 2000, International Journal of Dermatology.

[61]  A. Pandya,et al.  Disorders of hyperpigmentation. , 2000, Dermatologic clinics.

[62]  G. Bentham Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales , 1996, BMJ.

[63]  T. F. Cestari,et al.  Ultraviolet radiation decreases the granulomatous response to lepromin in humans. , 1995, The Journal of investigative dermatology.

[64]  D. Gawkrodger,et al.  Neuropeptide and neuronal marker studies in vitiligo , 1994, The British journal of dermatology.

[65]  T. Hamilton,et al.  Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. , 1994, Archives of dermatology.

[66]  T. Hamilton,et al.  Topical tretinoin (retinoic acid) improves melasma. A vehicle‐controlled, clinical trial , 1993, The British journal of dermatology.

[67]  W. Westerhof,et al.  Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. , 1993, The Journal of investigative dermatology.

[68]  M. d’Ischia,et al.  Mechanism of inhibition of melanogenesis by hydroquinone. , 1991, Biochimica et biophysica acta.

[69]  F. Fraschini,et al.  T cell subpopulations in vitiligo: a chronobiologic study. , 1990, Journal of the American Academy of Dermatology.

[70]  C. Summers,et al.  Visual anomalies associated with albinism. , 1990, Ophthalmic paediatrics and genetics.

[71]  H. Tagami,et al.  Therapeutic success of epidermal grafting in generalized vitiligo is limited by the Koebner phenomenon. , 1990, Journal of the American Academy of Dermatology.

[72]  T. Jenkins,et al.  Albinism and skin cancer in Southern Africa , 1989, Clinical genetics.

[73]  V. Dixit,et al.  Production and utilization of extracellular matrix components by human melanocytes. , 1989, Experimental cell research.

[74]  R. Falabella Treatment of localized vitiligo by autologous minigrafting. , 1988, Archives of dermatology.

[75]  H. Hönigsmann,et al.  Treatment of vitiligo with khellin and ultraviolet A. , 1988, Journal of the American Academy of Dermatology.

[76]  A. Sober,et al.  Chemical and pharmacologic agents that cause hyperpigmentation or hypopigmentation of the skin. , 1988, Dermatologic clinics.

[77]  A. Rebora,et al.  Racial differences in experimental skin infection with Candida albicans. , 1988, Acta dermato-venereologica.

[78]  M. Yasutomi,et al.  Migration of epidermal melanophores to the dermis through the basement membrane during metamorphosis in the frog, Rana japonica. , 1987, Pigment cell research.

[79]  A. P. Kelly,et al.  Natural cell-mediated cytotoxicity in vitiligo. , 1987, Journal of the American Academy of Dermatology.

[80]  R. Halaban,et al.  Transplantation of human melanocytes. , 1987, The Journal of investigative dermatology.

[81]  D. F. Roberts,et al.  Differentiation of heterozygotes in recessive albinism. , 1986, Journal of medical genetics.

[82]  T. Jenkins,et al.  Prevalence of albinism in the South African negro. , 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[83]  M. Mihm,et al.  Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. , 1981, Journal of the American Academy of Dermatology.

[84]  A. Peserico,et al.  Vitiligo and autoimmune polyendocrine deficiencies with autoantibodies to melanin-producing cells. , 1979, Archives of dermatology.

[85]  M. Porro,et al.  The monoene fatty acids of human surface lipids and their relation to skin melanogenesis , 1977 .

[86]  J. Parrish,et al.  Monobenzylether of hydroquinone , 1977, The British journal of dermatology.

[87]  J. Parrish,et al.  Photochemotherapy of vitiligo. Use of orally administered psoralens and a high-intensity long-wave ultraviolet light system. , 1976, Archives of dermatology.

[88]  R. N. Macsween,et al.  Serum anti‐tumour antibodies and auto‐antibodies in vitiligo , 1975, The British journal of dermatology.

[89]  T. Fitzpatrick,et al.  Mechanism of depigmentation by hydroquinone. , 1974, The Journal of investigative dermatology.

[90]  E. Kandil Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol--a double-blind trial. , 1974, The British journal of dermatology.

[91]  H. Cameron,et al.  Nephrotic Syndrome in Adult Africans in Nairobi , 1972, British medical journal.

[92]  S. Bleehen,et al.  TREATMENT OF VITILIGO WITH ORAL 4,5′,8‐TRIMETHYLPSORALEN (TRISORALEN) , 1972, The British journal of dermatology.

[93]  A. Lerner On the etiology of vitiligo and gray hair. , 1971, The American journal of medicine.

[94]  G. Kahn Depigmentation Caused by Phenolic Detergent Germicides , 1971 .

[95]  T. Ryan,et al.  FIBRINOLYTIC ACTIVITY IN LESIONS PRODUCED BY MONOCHROMATOR ULTRAVIOLET IRRADIATION IN VARIOUS PHOTODERMATOSES , 1970, The British journal of dermatology.

[96]  R. Dawber Clinical associations of vitiligo , 1970, Postgraduate medical journal.

[97]  David J. Wolf,et al.  Poikiloderma vasculare atrophicans , 1970, Cancer.

[98]  T. Fitzpatrick,et al.  Depigmentation of skin with 4-isopropylcatechol, mercaptoamines, and other compounds. , 1968, The Journal of investigative dermatology.

[99]  M. Corcos The clinical dynamics of pigment loss (a study of 71 lesions in eastern Nigerians). , 1966, Leprosy review.

[100]  M. Birbeck,et al.  An Electron Microscope Study of Basal Melanocytes and High-Level Clear Cells (Langerhans Cells) in Vitiligo * , 1961 .

[101]  L. Schwartz,et al.  Occupational Leukoderma. Preliminary Report. , 1939 .